Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory system. A number of preclinical studies have provided evidence for the involvement of cytokines, predominantly secreted by a variety of immune cells and by glial cells from the nervous system, in neuropathic pain conditions. Clinical trials and the use of anti-cytokine drugs in different neuropathic aetiologies support the relevance of cytokines as treatment targets. However, the use of such drugs, in particularly biotherapies, can provoke notable adverse effects. Moreover, it is challenging to select one given cytokine as a target, among the various neuropathic pain conditions. It could thus be of interest to target other proteins, such as growth factors, in order to act more widely on the neuroinflammation network. Thus, platelet-rich plasma (PRP), an autologous blood concentrate, is known to contain a natural concentration of growth factors and immune system messengers and is widely used in the clinical setting for tissue regeneration and repair.

中文翻译：

---

神经性疼痛中富含血小板的血浆和细胞因子：叙述性回顾和临床观点

神经性疼痛是影响躯体感觉系统的病变或疾病的直接后果。许多临床前研究提供了细胞因子参与的证据，细胞因子主要由多种免疫细胞和神经系统的神经胶质细胞分泌，参与神经性疼痛。临床试验和在不同神经病病因中使用抗细胞因子药物支持细胞因子作为治疗靶点的相关性。然而，使用此类药物，特别是生物疗法，会引起明显的副作用。此外，在各种神经性疼痛状况中选择一种给定的细胞因子作为靶标具有挑战性。因此，为了更广泛地作用于神经炎症网络，靶向其他蛋白质（例如生长因子）可能是有意义的。因此，富含血小板的血浆（PRP），